155 related articles for article (PubMed ID: 15925422)
1. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates.
Kim SK; Lee EH; Vaishali B; Lee S; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2005 Jun; 105(1-2):32-42. PubMed ID: 15925422
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.
Kim SK; Vaishali B; Lee E; Lee S; Lee YK; Kumar TS; Moon HT; Byun Y
Thromb Res; 2006; 117(4):419-27. PubMed ID: 15913716
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Lim KM; Moon HT; Kim CY; Byun Y
Thromb Haemost; 2011 Jun; 105(6):1060-71. PubMed ID: 21437357
[TBL] [Abstract][Full Text] [Related]
5. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
6. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent.
Lee Y; Nam JH; Shin HC; Byun Y
Circulation; 2001 Dec; 104(25):3116-20. PubMed ID: 11748110
[TBL] [Abstract][Full Text] [Related]
7. Prevention effect of orally active heparin derivative on deep vein thrombosis.
Kim SK; Lee DY; Kim CY; Moon HT; Byun Y
Thromb Haemost; 2006 Aug; 96(2):149-53. PubMed ID: 16894457
[TBL] [Abstract][Full Text] [Related]
8. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
Kim SK; Lee DY; Lee E; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2007 Jul; 120(1-2):4-10. PubMed ID: 17490773
[TBL] [Abstract][Full Text] [Related]
9. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Kim SK; Lee DY; Kim CY; Nam JH; Moon HT; Byun Y
J Control Release; 2007 Nov; 123(2):155-63. PubMed ID: 17884230
[TBL] [Abstract][Full Text] [Related]
10. Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies.
Ito Y; Kusawake T; Prasad YV; Sugioka N; Shibata N; Takada K
Int J Pharm; 2006 Jul; 317(2):114-9. PubMed ID: 16631328
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant efficacy of solid oral formulations containing a new heparin derivative.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Moon HT; Kim CY; Byun Y
Mol Pharm; 2010 Jun; 7(3):836-43. PubMed ID: 20349950
[TBL] [Abstract][Full Text] [Related]
12. Oligomeric bile acid-mediated oral delivery of low molecular weight heparin.
Al-Hilal TA; Park J; Alam F; Chung SW; Park JW; Kim K; Kwon IC; Kim IS; Kim SY; Byun Y
J Control Release; 2014 Feb; 175():17-24. PubMed ID: 24333628
[TBL] [Abstract][Full Text] [Related]
13. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system.
Hoffart V; Lamprecht A; Maincent P; Lecompte T; Vigneron C; Ubrich N
J Control Release; 2006 Jun; 113(1):38-42. PubMed ID: 16697485
[TBL] [Abstract][Full Text] [Related]
14. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation.
Paliwal R; Paliwal SR; Agrawal GP; Vyas SP
Int J Pharm; 2012 Jan; 422(1-2):179-84. PubMed ID: 22079712
[TBL] [Abstract][Full Text] [Related]
15. Biomimetic solid lipid nanoparticles for oral bioavailability enhancement of low molecular weight heparin and its lipid conjugates: in vitro and in vivo evaluation.
Paliwal R; Paliwal SR; Agrawal GP; Vyas SP
Mol Pharm; 2011 Aug; 8(4):1314-21. PubMed ID: 21598996
[TBL] [Abstract][Full Text] [Related]
16. Prevention effect of orally active heparin conjugate on cancer-associated thrombosis.
Al-Hilal TA; Alam F; Park JW; Kim K; Kwon IC; Ryu GH; Byun Y
J Control Release; 2014 Dec; 195():155-61. PubMed ID: 24862320
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo investigation of low molecular weight heparin-alginate beads for oral administration.
Iskenderoğlu C; Acartürk F; Erdoğan D; Bardakçi Y
J Drug Target; 2013 May; 21(4):389-406. PubMed ID: 23350807
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical conjugation with deoxycholic acid and dimethylsulfoxide for heparin oral delivery.
Kim SK; Huh J; Kim SY; Byun Y; Lee DY; Moon HT
Bioconjug Chem; 2011 Jul; 22(7):1451-8. PubMed ID: 21627301
[TBL] [Abstract][Full Text] [Related]
19. The novel formulation design of O/W microemulsion for improving the gastrointestinal absorption of poorly water soluble compounds.
Araya H; Tomita M; Hayashi M
Int J Pharm; 2005 Nov; 305(1-2):61-74. PubMed ID: 16219433
[TBL] [Abstract][Full Text] [Related]
20. Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis.
Hwang SR; Seo DH; Al-Hilal TA; Jeon OC; Kang JH; Kim SH; Kim HS; Chang YT; Kang YM; Yang VC; Byun Y
J Control Release; 2012 Nov; 163(3):374-84. PubMed ID: 23041275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
